By Chris Wack
Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.
The biopharmaceutical company said icotrokinra is a targeted oral peptide that selectively blocks the IL-23 receptor in adults with moderately to severely active ulcerative colitis.
Protagonist said the study met its primary endpoint of clinical response in all icotrokinra dose groups evaluated. The study also demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remission, symptomatic remission and endoscopic improvement at week 12.
Icotrokinra had a response rate of 63.5% for patients treated with the highest dose at week 12, versus 27% for placebo. Clinical remission and response rates continued to improve through week 28.
Icotrokinra was well tolerated with the proportions of participants reporting one or more adverse events being similar between the icotrokinra dose groups and the placebo group.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 10, 2025 09:44 ET (13:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。